EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

William H Gmeiner, Charles Chidi Okechukwu

Cancer Drug Resistance · 2023 · 6 (2) · 257-272

DOI: 10.20517/cdr.2022.136 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, 2023. Verfasst von William H Gmeiner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. Die Arbeit wurde bisher 112-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of chemoresistant disease during chemotherapy with 5-Fluorouracil-based (5-FU-based) regimens is an important factor in the mortality of metastatic CRC (mCRC). The causes of 5-FU resistance are multi-factorial, and besides DNA mismatch repair deficiency (MMR-D), there are no widely accepted criteria for determining which CRC patients are not likely to be responsive to 5-FU-based therapy. Thus, there is a need to systematically understand the mechanistic basis for 5-FU treatment failure and an urgent need to develop new approaches for circumventing the major causes of 5-FU resistance. In this manuscript, we review mechanisms of 5-FU resistance with an emphasis on: (1) altered anabolic metabolism limiting the formation of the primary active metabolite Fluorodeoxyuridylate (5-Fluoro-2'-deoxyuridine-5'-O-monophosphate; FdUMP); (2) elevated expression or activity of the primary enzymatic target thymidylate synthase (TS); and (3) dysregulated programmed cell death as important causes of 5-FU resistance. Importantly, these causes of 5-FU resistance can potentially be overcome through the use of next-generation fluoropyrimidine (FP) polymers (e.g., CF10) that display reduced dependence on anabolic metabolism and more potent TS inhibitory activity.

Schlagwörter

Stichwörter der Autor:innen

5-FU resistanceFluoropyrimidinechemotherapycolorectal cancerprecision medicinethymidylate synthase

Autor:innen und Institutionen

  • Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
  • Integrative Physiology and Pharmacology Graduate Program, Institution, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Gmeiner, W. H., & Okechukwu, C. C. (2023). Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resistance, 6(2), 257-272. https://doi.org/10.20517/cdr.2022.136

Vancouver

Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resistance. 2023;6(2):257-272. doi:10.20517/cdr.2022.136

BibTeX
@article{Gmeiner2023,
  author = {Gmeiner, William H and Okechukwu, Charles Chidi},
  title = {Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects},
  journal = {Cancer Drug Resistance},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {257--272},
  doi = {10.20517/cdr.2022.136}
}
Kostenlos starten →